For Research Use Only

PCSK9 Polyclonal antibody

Catalog Number:27882-1-AP

Featured Product 10 Publications




Basic Information	Catalog Number: 27882-1-AP	GenBank Accession Number: NM_174936.3	Purification Method: Antigen affinity purification	
	Size: 150ul , Concentration: 600 ug/ml by Nanodrop; Source: Rabbit Isotype: IgG Immunogen Catalog Number: AG27254	GeneID (NCBI):	Recommended Dilutions:	
		255738 UNIPROT ID: Q8NBP7	WB: 1:500-1:2000 FC (Intra): 0.40 ug per 10^6 cells in a 100 µl suspension	
				Full Name:
		proprotein convertase subtilisin/kexin type 9		
		Calculated MW: 74 kDa		W:
		Observed MW: 72-78 kDa, 62 kDa		
		Applications	Tested Applications:	Positive Controls:
WB, FC (Intra), ELISA Cited Applications:			oG2 cells, rat liver tissue, mouse liver tissue	
WB, IHC, IF	FC (Intra		a) : HepG2 cells,	
Species Specificity: human, mouse, rat				
Cited Species:				
	human, mouse, rat			
Background Information	human, mouse, rat Proprotein convertase subtilisin/kex density lipoprotein-cholesterol (LDL- PCSK9 is expressed in the kidney an autocatalytic cleavage in the endopj fragment remains associated with th blood. The ability of PCSK9 to regula influence additional membrane prot treat cancer is also attractive becaus	-C), by virtue of its pivotal role in d lung. It is synthesized as a 72 kI lasmic reticulum to generate a 63 ne mature protein and is necessan the a diverse group of cell-surface teins that are important in anti-tur e two neutralizing antibodies aga	y for its secretion, allowing it to circulate in t proteins hinted that it might also be able to	
	human, mouse, rat Proprotein convertase subtilisin/kew density lipoprotein-cholesterol (LDL- PCSK9 is expressed in the kidney an autocatalytic cleavage in the endopl fragment remains associated with th blood. The ability of PCSK9 to regula influence additional membrane prot treat cancer is also attractive becaus already been approved for human cl	-C), by virtue of its pivotal role in d lung. It is synthesized as a 72 kI lasmic reticulum to generate a 63 ne mature protein and is necessan the a diverse group of cell-surface teins that are important in anti-tur e two neutralizing antibodies aga	the degradation of the LDL receptor (LDLR). Da immature precursor that undergoes kDa mature protein. The cleaved N-terminal y for its secretion, allowing it to circulate in t proteins hinted that it might also be able to mour immune responses. Targeting PCSK9 to ainst it, evolocumab and alirocumab, have	
	human, mouse, rat Proprotein convertase subtilisin/kew density lipoprotein-cholesterol (LDL- PCSK9 is expressed in the kidney an autocatalytic cleavage in the endopl fragment remains associated with th blood. The ability of PCSK9 to regula influence additional membrane prot treat cancer is also attractive becaus already been approved for human cl	-C), by virtue of its pivotal role in d lung. It is synthesized as a 72 kI lasmic reticulum to generate a 63 he mature protein and is necessan ite a diverse group of cell-surface leins that are important in anti-tur e two neutralizing antibodies age inical use to lower cholesterol lev	the degradation of the LDL receptor (LDLR). Da immature precursor that undergoes is kDa mature protein. The cleaved N-terminal y for its secretion, allowing it to circulate in t proteins hinted that it might also be able to mour immune responses. Targeting PCSK9 to ainst it, evolocumab and alirocumab, have yels. (PMID: 30522786, PMID: 22493497)	
Background Information	human, mouse, rat Proprotein convertase subtilisin/kew density lipoprotein-cholesterol (LDL- PCSK9 is expressed in the kidney an autocatalytic cleavage in the endopl fragment remains associated with th blood. The ability of PCSK9 to regula influence additional membrane prot treat cancer is also attractive becaus already been approved for human cl Author Pu Wanyun Dang 39	C), by virtue of its pivotal role in d lung. It is synthesized as a 72 kl lasmic reticulum to generate a 63 he mature protein and is necessan the a diverse group of cell-surface teins that are important in anti-tur e two neutralizing antibodies aga inical use to lower cholesterol lev bmed ID Journal	the degradation of the LDL receptor (LDLR). Da immature precursor that undergoes is kDa mature protein. The cleaved N-terminal y for its secretion, allowing it to circulate in to proteins hinted that it might also be able to mour immune responses. Targeting PCSK9 to ainst it, evolocumab and alirocumab, have vels. (PMID: 30522786, PMID: 22493497) Application	
	human, mouse, rat Proprotein convertase subtilisin/kew density lipoprotein-cholesterol (LDL- PCSK9 is expressed in the kidney an autocatalytic cleavage in the endopl fragment remains associated with th blood. The ability of PCSK9 to regular influence additional membrane prot treat cancer is also attractive becaus already been approved for human cl Author Pu Wanyun Dang 39 Ying Xu 39	C), by virtue of its pivotal role in d lung. It is synthesized as a 72 kl lasmic reticulum to generate a 63 he mature protein and is necessan the a diverse group of cell-surface leins that are important in anti-tur e two neutralizing antibodies againical use to lower cholesterol leve bmed ID Journal 769164 Int J Mol Sci	the degradation of the LDL receptor (LDLR). Da immature precursor that undergoes kDa mature protein. The cleaved N-terminal y for its secretion, allowing it to circulate in t proteins hinted that it might also be able to mour immune responses. Targeting PCSK9 to ainst it, evolocumab and alirocumab, have vels. (PMID: 30522786, PMID: 22493497) Application WB	
	human, mouse, rat Proprotein convertase subtilisin/kew density lipoprotein-cholesterol (LDL- PCSK9 is expressed in the kidney an autocatalytic cleavage in the endopl fragment remains associated with th blood. The ability of PCSK9 to regular influence additional membrane prot treat cancer is also attractive becaus already been approved for human cl Author Pu Wanyun Dang 39 Ying Xu 39	-C), by virtue of its pivotal role in d lung. It is synthesized as a 72 kl lasmic reticulum to generate a 63 he mature protein and is necessan the a diverse group of cell-surface eins that are important in anti-tur is two neutralizing antibodies againical use to lower cholesterol leve bmed ID Journal 769164 Int J Mol Sci 282119 PeerJ 241385 Phytomedicine ter shipment.	the degradation of the LDL receptor (LDLR). Da immature precursor that undergoes is kDa mature protein. The cleaved N-terminal y for its secretion, allowing it to circulate in to proteins hinted that it might also be able to mour immune responses. Targeting PCSK9 to ainst it, evolocumab and alirocumab, have yels. (PMID: 30522786, PMID: 22493497) Application WB IHC	


For technical support and original validation data for this product please contact: T: 1 (888) 4PTGLAB (1-888-478-4522) (toll free E: proteintech@ptglab.com in USA), or 1(312) 455-8498 (outside USA) W: ptglab.com

This product is exclusively available under Proteintech Group brand and is not available to purchase from any other manufacturer.


Selected Validation Data



Various lysates were subjected to SDS PAGE followed by western blot with 27882-1-AP (PCSK9 antibody) at dilution of 1:1000 incubated at room temperature for 1.5 hours.



WB result of PCSK9 antibody (27882-1-AP; 1:2000; incubated at room temperature for 1.5 hours) with sh-Control and sh-PCSK9 transfected HepG2 cells.



1X10^6 HepG2 cells were intracellularly stained with 0.4 ug Anti-Human PCSK9 (27882-1-AP) and Coralite®488-Conjugated Goat Anti-Rabbit IgG(H+L) at dilution 1:1000 (red), or 0.4 ug Control Antibody. Cells were fixed with 4% PFA and permeabilized with Flow Cytometry Perm Buffer (PF00011-C).